This is not the most recent version of the article. View current version (17 JUN 2014)

Intervention Protocol

You have free access to this content

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C

  1. Mieke H Lamers1,2,*,
  2. Mark Broekman1,
  3. Joost PH Drenth1,
  4. Christian Gluud2

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 27 MAY 2014

DOI: 10.1002/14651858.CD011132


How to Cite

Lamers MH, Broekman M, Drenth JPH, Gluud C. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD011132. DOI: 10.1002/14651858.CD011132.

Author Information

  1. 1

    Radboud University Medical Center Nijmegen, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands

  2. 2

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Mieke H Lamers, m.lamers@mdl.umcn.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 27 MAY 2014

SEARCH

This is not the most recent version of the article. View current version (17 JUN 2014)

References

Additional references

Altman 2003
Asselah 2010
Awad 2010
Bacon 2011
  • Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011;364(13):1207-17. [PUBMED: 21449784]
Brillanti 1999
  • Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Italian Journal of Gastroenterology and Hepatology 1999;31(2):130-4. [PUBMED: 10363198]
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
Brok 2009
Brok 2010
  • Brok J, Gluud LL, Gluud C. Ribavirin plus interferon vs. interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews (Online) 2010, (1):CD005445. [PubMed: 20839385]. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2]
Choo 1989
CTU 2011
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 8 May 2014).
Davis 1989
  • Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England Journal of Medicine 1989;321(22):1501-6.
Davis 1998
  • Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. New England Journal of Medicine 1998;339(21):1493-9.
De Clercq 2001
Deltenre 2004
  • Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. Journal of hepatology 2004;41(3):462-73. [PUBMED: 15336450]
DeMets 1987
DerSimonian 1986
Di Bisceglie 2011
Di Martino 2011
EASL 2014
Egger 1997
El-Serag 2003
  • El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of Internal Medicine 2003;139(10):817-23.
Ghany 2009
Gluud 2007
Gluud 2014
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 1. Art. No.: LIVER.
Hauser 2014a
Hauser 2014b
  • Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD005642.pub3]
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hollis 1999
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997.
Jacobson 2011
  • Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011;364(25):2405-16. [PUBMED: 21696307]
Kenny-Walsh 1999
Kim 2009
  • Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009;137(5):1680-6.
Kjaergard 2001
Koff 1980
Koretz 1993
Koretz 2013
Lamers 2014
  • Lamers MH, Broekman M, Drenth JPH, Gluud C. Aminoadamantanes for chronic hepatitis C. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD010125.pub2]
Lauer 2001
Lavanchy 2011
Lawitz 2013
  • Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine 2013;368(20):1878-87.
Lawitz 2013a
  • Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383(9916):515-23.
Lundh 2012
McHutchison 1998
  • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 1998;339(21):1485-92.
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
Myers 2002
  • Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000370]
Poordad 2011
  • Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011;364(13):1195-206. [PUBMED: 21449783]
Poynard 1998
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426-32.
Reichard 1991
Reichard 1993
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rodger 2000
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Savović 2012
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savović 2012a
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schultz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Seeff 2009
Sherman 2011
  • Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011;365(11):1014-24. [PUBMED: 21916639]
Simin 2007
Simmonds 2005
Smith 2004
Sulkowski 2014
  • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 2014;370(3):211-21.
Sy 2006
  • Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. International Journal of Medical Sciences 2006;3(2):41-6.
Thein 2008
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 8 May 2014).
Tine 1991
Ueno 2009
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
Wiese 2000
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
Zeuzem 2011